专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20040220537A1 Ocular treatment device 审中-公开
标题翻译：眼部治疗装置
公开(公告)号：US20040220537A1
公开(公告)日：2004-11-04
申请号：US10742497
申请日：2003-12-19
申请人： Pharmacia Aktiebolag
发明人： Jonathan K. Embleton , Stephen P. Jones , Richard J. Malcolmsen , Luigi G. Martini , Peter J. Houzego , Sarah A. Rocca , Howard N. Stevens
IPC分类号： A61M035/00
CPC分类号： B65D75/58 , A61F9/0008 , B05B9/0805
摘要： A unit container for a treatment fluid comprises a sealed enclosure of which one wall section thereof is formed with at least one opening. The enclosure is pressuriseable to discharge its contents thorough the opening or openings, which is or are of sufficient diameter to enable the generation of a jet and/or discrete droplets of treatment fluid discharged therefrom. The one wall section is typically a flat section of the enclosure wall, and the enclosure is typically a blister pack, with the wall section at a planar base of the blister. However the one wall section may be dome-shaped and formed with at least one opening in the top region of the dome. Containers of the invention may be provided in packages, for example in strip form or in planar arrays. Dispensing devices are described for discharging their content in treatment.
摘要翻译：用于处理流体的单元容器包括其一个壁部分形成有至少一个开口的密封外壳。外壳可加压，以通过开口或开口排出其内容物，该开口或开口具有足够的直径以使得能够产生从其排出的处理流体的喷射和/或离散液滴。一个壁部分通常是封闭壁的平坦部分，并且外壳通常是泡罩包装，其中壁部分处于泡罩的平面基部。然而，一个壁部分可以是圆顶形并且在圆顶的顶部区域中形成有至少一个开口。本发明的容器可以以包装形式提供，例如带状或平面阵列。描述分配装置用于在处理中排出其内容物。

2. 发明申请

US20040167190A1 Prostagladin derivatives for the treatment of glaucoma or ocular hypertension 失效
标题翻译：前列腺素衍生物用于治疗青光眼或高眼压症
公开(公告)号：US20040167190A1
公开(公告)日：2004-08-26
申请号：US10723140
申请日：2003-11-25
申请人： Pharmacia Aktiebolag
发明人： Johan Wilhelm Stjernschantz , Bahram Resul
IPC分类号： A61K031/557
CPC分类号： A61K31/557 , A61K31/5575 , A61K31/5578 , C07C405/00
摘要： The invention relates to ophthalmological compositions for topical treatment of glaucoma or ocular hypertension comprising an effective intraocular pressure reducing amount of a prostaglandin derivative of PGA, PGB, PGD, PGE or PGF, in which the omega chain contains a ring structure, in an ophthalmologically compatible carrier. The invention further relates to the preparation of said compositions and their use for treatment of glaucoma or ocular hypertension.
摘要翻译：本发明涉及用于局部治疗青光眼或高眼压症的眼科学组合物，其包含有效眼压降低量的PGA，PGB，PGD，PGE或PGF的前列腺素衍生物，其中ω链含有环结构，在眼科学上相容载体本发明还涉及所述组合物的制备及其用于治疗青光眼或高眼压症的用途。

3. 发明申请

WO1984003704A1 3-PHOSPHATIDYL ESTERS FOR USE AS A LAXATIVE FOR RECTAL ADMINISTRATION 审中-公开
标题翻译：用作立体管理用途的3-磷酸酯酯
公开(公告)号：WO1984003704A1
公开(公告)日：1984-09-27
申请号：PCT/SE1984000105
申请日：1984-03-23
申请人： PHARMACIA AKTIEBOLAG , EMBRING, Paul, Gunnar
发明人： PHARMACIA AKTIEBOLAG
IPC分类号： C07F09/08
CPC分类号： C07F9/117 , A61K31/66 , C07F9/091 , C07F9/10 , A61K31/14 , A61K2300/00
摘要： One or more water-soluble 3-phosphatidyl esters of the formula (I), in which R1 and R2 are the same or different and each signifies the acyl group of a saturated or unsaturated fatty acid having 10-22 C-atoms, and R3 signifies the residue of a pentavalent or hexavalent alcohol, preferably in mixture with choline, for use as a rectally administrable laxative, process of preparing them, and medicinal compositions containing them.
摘要翻译：一种或多种式（I）的水溶性3-磷脂酰基酯，其中R 1和R 2相同或不同，表示具有10-22个C原子的饱和或不饱和脂肪酸的酰基，R3 表示五价或六价醇的残留物，优选与胆碱混合，用作直肠给药的泻药，制备方法和含有它们的药物组合物。

4. 发明申请

WO1983002391A1 A PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING ISCHEMIC CELL DAMAGE AND METHODS FOR THE USE AND PREPARATION THEREOF 审中-公开
标题翻译：一种用于预防和治疗异位细胞损伤的药物组合物及其使用及其制备方法
公开(公告)号：WO1983002391A1
公开(公告)日：1983-07-21
申请号：PCT/SE1983000003
申请日：1983-01-14
申请人： PHARMACIA AKTIEBOLAG , HULTMAN, Jan, Lennart , RONQUIST, Gunnar
发明人： PHARMACIA AKTIEBOLAG
IPC分类号： A61K31/66
CPC分类号： A61K31/66 , A61K31/70 , A61K2300/00
摘要： A pharmaceutical composition for preventing and treating ischemic cell damage, which composition contains a physiologically acceptable, water- soluble salt of phosphoenolpyruvic acid and a physiologically acceptable, water-soluble salt of adenosine-5'-triphosphoric acid in a mutual ratio of from 5:1 to 1000:1, preferably from 10:1 to 500:1, calculated on a molar basis. A method of preventing and treating ischemic cell damage by administering such a composition is also disclosed as well as a method for the preparation of said composition by dissolving said salts in a physiologically acceptable aqueous liquid, adjusting the pH value of the solution, sterilizing and, when desired, freeze-drying.
摘要翻译：一种用于预防和治疗缺血性细胞损伤的药物组合物，该组合物含有生理上可接受的磷酸烯醇式丙酮酸的水溶性盐和生理上可接受的水溶性腺苷-5'-三磷酸盐，相互比例为5： 1至1000:1，优选10：1至500：1，以摩尔计算。还公开了通过施用这种组合物来预防和治疗缺血性细胞损伤的方法，以及通过将所述盐溶解在生理学上可接受的水性液体中，调节溶液的pH值，灭菌和/ 当需要时，冷冻干燥。

5. 发明申请

WO1984004525A1 A METHOD FOR SPLITTING DI-SULPHIDE BONDS AND A COMPOUND OBTAINED THEREBY 审中-公开
标题翻译：一种用于分离二硫化铅和一种获得的化合物的方法
公开(公告)号：WO1984004525A1
公开(公告)日：1984-11-22
申请号：PCT/SE1984000186
申请日：1984-05-16
申请人： PHARMACIA AKTIEBOLAG , AXÉN, Rolf, Erik, Axel, Verner , CARLSSON, Jan, Per, Erik , DREVIN, Hakan, Nils, Yngve
发明人： PHARMACIA AKTIEBOLAG
IPC分类号： C07G07/00
CPC分类号： C07K1/122 , C07B45/06 , C07K1/067 , C07K16/00 , G01N33/53 , G01N33/535 , Y10S424/809 , Y10S530/862 , Y10S530/866
摘要： There is described a method for splitting at least one disulphide bond -S-S-, where each of the sulphur atoms is directly bound covalently to its respective aliphatic carbon atom in an organic substance which contains at least one such disulphide bond, in which each bond -S-S- which is split is converted substantially to two reactive groups of the formulae -S-S-R1 and R2-S-S-, where R1 and R2 are equal or different and each is an organic residue. Splitting of the bond is effected by reacting said organic substance with a mixture of a compound R3-S-S-R4 and a compound capable of existing in the tautomeric forms R5-S-H and HR5 = S or corresponding resonance-stabilised anion forms, in which compounds the residues R3, R4 and R5 i) are organic residues of which all are different, two are equal or all are equal, and ii) are defined in a) that each of the aforesaid sulphur atoms in the compounds R3-S-S-R4 and R5-S-H is bound to a carbon atom in an aromatic ring and b) that under prevailing splitting conditions a compound R3-S-H or R4-S-H released by the reaction of the compound R3-S-S-R4 and the compound R5-S-H exist substantially in their tautomeric forms HR3 = S, HR4 = S and HR5 = S respectively, or corresponding resonance-stabilized anion forms. In each of the groups -S-S-R1 and R2-S-S- produced by splitting the disulphide bond, R1 and R2 are each a residue of the group which consists of R3, R4 and R5. The invention also relates to an organic compound produced by the aforesaid splitting and exhibiting at least one group -S-S-R1 and/or R2-S-S- bound covalently to an aliphatic carbon atom, in which groups R1 and R2 have the aforegiven significance.

6. 发明专利

AT6252T 未知
公开(公告)号：AT6252T
公开(公告)日：1984-03-15
申请号：AT81102068
申请日：1981-03-19
申请人： PHARMACIA AKTIEBOLAG
发明人： AGBACK, KARL HUBERG , NYGREN, ALF SIGURD
IPC分类号： A61K31/19 , A61K31/655 , A61P1/00 , A61P1/04 , C07C67/00 , C07C241/00 , C07C245/08 , C07C301/00 , C07C303/30 , C07C309/04 , C07C309/29 , C07C309/66 , C07C309/73 , C09B29/14 , C09B43/24 , C07C107/06
摘要： A method of preparing 3,3'-azo-bis-(6-hydroxy benzoic acid) of formula I I and salts thereof in at least 98% purity for treating inflammatory intestinal diseases. According to the invention a compound II II is diazotized, and the diazonium salt obtained is coupled with a compound III III The formed intermediate IV, which is also comprised by the invention, IV is hydrolized in alkaline medium to form the compound I. R1, R2 and R3 signify lower alkyl, R2 also possibly substituted phenyl.

7. 发明公开

EP1348437A2 Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension 失效
标题翻译： Prostaglandinderivative zur Behandlung von Glaukoma oderokuläre高血压
公开(公告)号：EP1348437A2
公开(公告)日：2003-10-01
申请号：EP03014533.8
申请日：1989-09-06
申请人： Pharmacia Aktiebolag
发明人： Stjernschantz, Johan W. , Resul, Bahram
IPC分类号： A61K31/5575
CPC分类号： C07C405/00 , A61K31/557 , A61K31/5575 , A61K31/5578 , Y10S514/913
摘要： The present invention relates to the use of a derivative of prostaglandin PGF for the preparation of an ophthalmological composition for the treatment of glaucoma or ocular hypertension. The present invention also relates to ophthalmological compositions.
摘要翻译：本发明涉及前列腺素PGF衍生物在制备用于治疗青光眼或高眼压症的眼科组合物中的用途。本发明还涉及眼科学组合物。本发明涉及前列腺素PGF的衍生物在制备用于治疗青光眼或高眼压症的眼科组合物中的用途。本发明还涉及眼科学组合物。

8. 发明授权

EP1056415B1 MEDICAL IMPLANTS OF STRETCH-CRYSTALLIZABLE ELASTOMERS AND METHODS OF IMPLANTATION 有权
标题翻译：的医学植入物从植入可拉伸结晶弹性体和方法
公开(公告)号：EP1056415B1
公开(公告)日：2003-05-28
申请号：EP99908141.7
申请日：1999-02-12
申请人： Pharmacia Aktiebolag
发明人： HUO, Peter, P. , ZHOU, Stephen, Q. , LIAU, Christine, J., Y.
IPC分类号： A61F2/16 , A61L27/18 , G02B1/04
CPC分类号： G02B1/043 , A61L27/18 , A61L2430/16 , C08L83/08
摘要： Reduced trauma medical implants (10), and methods for their use are disclosed wherein at least a portion of the implant is formed of a stretch crystallizable elastomeric material formulated to exhibit the property of stretch crystallization upon substantial elongation of the implant to form stable, small incision implant configurations having at least one dimension substantially reduced for insertion through a surgical incision that is small relative to the incision size necessary to implant the un-stretched implant. Exemplary embodiments include intraocular implants formed of optically clear, high refractive index stretch crystallizable silicone elastomers formulated to stretch crystalize at near ambient temperatures upon elongations greater than or equal to 300 %, and to recover their original configuration immediately upon exposure to body temperature following implantation.

9. 发明公开

EP1300151A3 Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension 失效
标题翻译：前列腺素衍生物用于治疗青光眼或高眼压症
公开(公告)号：EP1300151A3
公开(公告)日：2003-05-14
申请号：EP03000518.5
申请日：1989-09-06
申请人： Pharmacia Aktiebolag
发明人： Stjernschantz, Johan W. , Resul, Bahram
IPC分类号： A61K31/557 , A61P27/06
CPC分类号： A61K31/5575 , A61K31/557
摘要： The present invention relates to the use of a derivative of prostaglandin PGA, PGE or PGF for the preparation of an ophthalmological composition for the treatment of glaucoma or ocular hypertension. The present invention also relates to ophthalmological compositions.
摘要翻译：本发明涉及前列腺素PGA，PGE或PGF的衍生物在制备用于治疗青光眼或高眼压症的眼科组合物中的用途。本发明还涉及眼科组合物。

10. 发明公开

EP1300150A3 Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension 失效
公开(公告)号：EP1300150A3
公开(公告)日：2003-05-14
申请号：EP03000517.7
申请日：1989-09-06
申请人： Pharmacia Aktiebolag
发明人： Stjernschantz, Johan W. , Resul, Bahram
IPC分类号： A61K31/557 , A61P27/06
CPC分类号： A61K31/5575 , A61K31/557
摘要： The present invention relates to the use of a derivative of prostaglandin PGF for the preparation of an ophthalmological composition for the treatment of glaucoma or ocular hypertension. The present invention also relates to ophthalmological compositions.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式